Left Atrial Volume Changes Who Underwent Cardioversion and Recurrence of AF After RF Ablation in Persistent AF (SAFE-AF)
Recruiting
Observational Study
Persisent Atrial Fibrillation
Reversal of Atrial Enlargement
Recurrence of Atrial Fibrillation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Electrical/pharmacological cardioversion improves structural remodeling of left atrium. We hypothesize that persistent atrial fibrillation (AF) patients with more significant left atrial size reduction after cardioversion have lower AF recurrence rates following radiofrequency ablation. The aim is to evaluate the relationship between changes in left atrial size 3 to 6 months after cardioversion an…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients with estabolished diagnosis of Persistent Atrial Fibrillation during past 6 mnths.
2. LAD brfore entering the two cohorts is more than 40mm, and less than 50mm.
3. Pharmacological or electrical cardioversion has be performed successfully.
4. At least two echocardiogr…
Contacts